INSPHERO
A stranger
UNLOOC: Unlocking data content of Organ On Chips
The launch of a novel drug to the market is preceded by clinical testing and validation both on animal in vitro and in vivo models. Animal m...
2024-06-28 - 2027-04-30 | financed
2024-06-28 - 2027-04-30 | financed
Moore4Medical: Accelerating Innovation in Microfabricated Medical Devices
INSPHERO AG
participó en un
H2020
H2020-ECSEL-2019-1-IA-two-stage
Compared to the pace of innovation in electronic consumer products, the pace of innovation for medical devices is lagging behind. It is the...
2020-05-19 - 2023-09-30 | financed
2020-05-19 - 2023-09-30 | financed
ARON: Assay Ready Organ Network
INSPHERO AG
processed a
H2020
H2020-EIC-SMEInst-2018-2020
In drug development, there is an urgent need for more physiological and predictive pre-clinical in-vitro assays to test the efficacy and tox...
2019-12-06 - 2020-06-30 | financed
2019-12-06 - 2020-06-30 | financed
PATROLS: Physiologically Anchored Tools for Realistic nanOmateriaL hazard aSsessment
INSPHERO AG
participó en un
H2020
H2020-NMBP-2016-2017
Nanotechnology promises significant scientific, economic and societal benefits, but commercialization and growth are threatened by safety un...
2017-10-30 - 2021-09-30 | financed
2017-10-30 - 2021-09-30 | financed
LSFM4LIFE: Production and characterization of endocrine cells derived from human pancreas organoids for the cel...
INSPHERO AG
participó en un
H2020
H2020-PHC-2014-2015
Self-renew and multilineage potential characterize stem cells. We have recently described that pancreas progenitor cells extracted from adu...
2015-12-03 - 2019-12-31 | financed
2015-12-03 - 2019-12-31 | financed
EU-ToxRisk: An Integrated European Flagship Program Driving Mechanism based Toxicity Testing and Risk Assessme...
INSPHERO AG
participó en un
H2020
H2020-PHC-2014-2015
The vision of EU-ToxRisk is to drive a paradigm shift in toxicology towards an animal-free, mechanism-based integrated approach to chemical...
2015-09-11 - 2021-12-31 | financed
2015-09-11 - 2021-12-31 | financed
MATRIXASSAY: Novel Cell Migration Assay Based on Microtissue Technology and Tissue Specific Matrices
INSPHERO AG
participó en un
H2020
H2020-MSCA-RISE-2014
Cell migration assays are commonly used to study wound healing, cancer cell invasion, and tissue development. Problems associated with the g...
2015-04-23 - 2019-05-31 | financed
2015-04-23 - 2019-05-31 | financed
BOC: The Body on a Chip BoC
INSPHERO AG
processed a
FP7
High attrition and failures rates in pharmaceutical and biotechnological drug development require a paradigm change towards more physiologic...
financed
financed
HECATOS: Hepatic and Cardiac Toxicity Systems modelling
INSPHERO AG
participó en un
FP7
HeCaToS aims at developing integrative in silico tools for predicting human liver and heart toxicity. The objective is to develop an integra...
financed
financed
* No data from the current company are not available.